Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
OpenAI Rejects Apple Trade Secret Theft Claims 
Add as a preferred source on Google
BOSTON, March 06, 2018 -- Keryx Biopharmaceuticals, Inc, (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced it will webcast its corporate presentation at the 38th Annual Cowen Healthcare Conference in Boston on Monday, March 12, 2018 at 1:30 p.m. ET.
A live audio webcast of both the presentation and breakout session will be accessible from Keryx’s website at http://investors.keryx.com within the Investor Relations section under “webcasts and presentations.” Archived versions of the webcasts will be available for at least 15 days following the conclusion of each session.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc., with headquarters in Boston, Massachusetts, is focused on the development and commercialization of innovative medicines that provide unique and meaningful advantages to people with kidney disease. The Keryx team consists of more than 200 committed people working with passion to advance the care of people with this complex disease. This dedication has resulted in two FDA-approved indications for Keryx’s first medicine, Auryxia® (ferric citrate) tablets.
KERYX BIOPHARMACEUTICALS CONTACT:
Amy Sullivan
T: 617-466-3519
[email protected]
